The most common substitution question in this group, and the one where the evidence gap is widest. hGH is a regulated drug with decades of trial data. CJC-1295 is a research compound usually sold in a form that was never trialed.
Side by side
| HGH (Somatropin) | CJC-1295 | |
|---|---|---|
| Class | Recombinant human growth hormone | GHRH analog |
| Status | FDA approved (somatropin brands); gray-market generics unapproved | Research compound |
| Route | Subcutaneous injection | Subcutaneous injection |
| Typical vials | 10 IU, 12 IU, 24 IU, 36 IU | 2 mg, 5 mg, 10 mg |
| Dose range | 1 IU to 4 IU | 100 mcg to 300 mcg |
| Frequency | Once daily, often 5 to 7 days per week | 1 to 3 times daily (no DAC) |
| Half-life | ~3 hours | No human data |
| Dosing unit | IU | micrograms |
Pharmacokinetics
No curves are shown, on purpose.
No published human pharmacokinetics for CJC-1295. Drawing one curve against an absent one would imply a comparison that cannot be made.
What the evidence supports
These grade how well each outcome has been studied in humans, never how well either compound works. A strong grade can sit on a negative result.
Both top out at the same tier of evidence: Human RCT. Where they differ is in which outcomes have been asked about, not in how well either has been studied overall.
HGH (Somatropin)
| Outcome | Evidence |
|---|---|
| Body composition in diagnosed GH deficiency | Human RCT |
| Growth in GH-deficient children | Human RCT |
| Body composition in healthy adults | Human, observational |
| Anti-aging outcomes in healthy adults | No data |
CJC-1295
| Outcome | Evidence |
|---|---|
| Raises GH and IGF-1 (with DAC) | Human RCT |
| Body composition change | No data |
| Sleep quality | No data |
How to choose
hGH has the evidence and the legal weight
Approved, extensively studied, and a controlled prescription drug in most countries.
CJC-1295 is not a cheaper hGH
It works upstream, so its ceiling is whatever the pituitary can release, and the commonly sold no-DAC version behaves very differently from the trialed compound.
Neither is supported for the use most people want
hGH's data is in deficiency. CJC-1295 has no outcome data at all.
At the syringe
At the default setup on each compound's own page, a 10 IU vial in 2 mL puts 0.05 IU on every insulin unit, while a 5 mg vial in 2 mL puts 25 mcg on every unit. That is the number that decides whether a dose lands on a readable mark, and it is set by how much water goes in, not by the compound.